Predictors of mortality from pulmonary embolism and their influence on clinical management

• References

• 1 Silverstein MD, Heit JA, Mohr DN. et al. Trends in the incidence of deep vein thrombosis and pulmonary embolism: a 25-year population-based study. Arch Intern Med 1998; 158: 585-593.
• 2 Spencer FA, Emery C, Lessard D. et al. The Wor-cester venous thromboembolism study. A population-based study of the clinical epidemiology of venous thromboembolism. J Gen Intern Med 2006; 21: 722-727.
• 3 Lilienfield DE. Decreasing mortality from pulmonary embolism in the United States 1979-1996. Int J Epidemiol 2000; 29: 465-469.
• 4 Cohen AT, Agnelli G, Anderson FA, Arcelus JI. et al. for the VTE Impact Assessment Group in Europe (VITAE) Venous thromboembolism (VTE) in Europe The number of VTE events and associated morbidity and mortality. Thromb Haemost. 2007; 98: 756-764.
• 5 Konstantinides S. Recurrent venous thromboembolism: quite harmless after all?. Thromb Haemost 2008; 99: 655-656.
• 6 Goldhaber SZ, Visani L, De Rosa M. Acute pulmonary embolism: clinical outcomes in the International Cooperative Pulmonary Embolism Registry. Lancet 1999; 353: 1386-1389.
• 7 Konstantinides S, Geibel A, Olschewski M. et al. Association Between Thrombolytic Treatment and the Prognosis of Haemodynamically Stable Patients With Major Pulmonary Embolism. Circulation 1997; 96: 882-886.
• 8 Heit J, Silverstein M, Mohr D. et al. Predictors of survival after deep vein thrombosis and pulmonary embolism. Arch Intern Med 1999; 159: 445-453.
• 9 Wood KE. Major pulmonary embolism: review of a pathophysiologic approach to the golden hour of hemodynamically significant pulmonary embolism. Chest 2002; 121: 877-905.
• 10 Dalen J. Pulmonary embolism: what have we learned since Virchow?: Treatment and prevention. Chest 2002; 122: 1801-1817.
• 11 Quinlan DJ, McQuillan A, Eikelboom JW. Lowmolecular-weight heparin compared with intravenous unfractionated heparin for treatment of pulmonary embolism: a meta-analysis of randomized, controlled trials. Ann Intern Med 2004; 140: 175-183.
• 12 Adams JE, Bodor GS, Davila-Roman VG. et al. Cardiac troponin I: a marker with high specificity for cardiac injury. Circulation 1993; 88: 101-106.
• 13 Kucher N, Rossi E, De Rosa M. et al. Massive pulmonary embolism. Circulation 2006; 113: 577-582.
• 14 Buller HR, Agnelli G, Hull RD. et al. Antithrombotic therapy for venous thromboembolic disease: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004; 126: 401S-428S.
• 15 Tapson VF. Acute pulmonary embolism. N Eng J Med 2008; 358: 1037.
• 16 Aujesky D, Perrier A, Roy PM. et al. Validation of a clinical prognostic model to identify low-risk patients with pulmonary embolism. J Intern Med 2007; 261: 597-604.
• 17 Wicki J, Perrier A, Perneger TV. et al. Predicting adverse outcome in patients with acute pulmonary embolism: a risk score. Thromb Haemost 2000; 84: 548-552.
• 18 Ribeiro A, Lindmarker P, Juhlin-Dunnfelt A. et al. Echocardiography doppler in pulmonary embolism: right ventricular dysfunction as a predictor of mortality rate. Am Heart J 1997; 134: 479-487.
• 19 Kasper W, Konstantinides S, Geibel A. et al. Prognostic significance of right ventricular afterload stress detected by echocardiography in patients with clinically suspected pulmonary embolism. Heart 1997; 77: 346-349.
• 20 Grifoni S, Olivotto I, Cecchini P. et al. Short term clinical outcome of patients with pulmonary embolism, normal blood pressure and echocardiographycal right ventricular dysfunction. Circulation 2000; 101: 2817-2822.
• 21 Kucher N, Rossi E, De Rosa M. et al. Prognostic role of echocardiography among patients with acute pulmonary embolism and a systolic arterial pressure of 90 mm Hg or higher. Arch Intern Med 2005; 165: 1777-1781.
• 22 Fremont B, Pacouret G, Jacobi D. et al. Prognostic value of the echocardiographic right/left ventricular end-diastolic diameter ratio in patients with acute pulmonary embolism : results from a monocenter registry of 1416 patients. Chest 2008; 133: 358-362.
• 23 Sanchez O, Trinquart L, Colombet I. et al. Prognostic value of right ventricular dysfunction in patients with haemodynamically stable pulmonary embolism: a systematic review. Eur Heart J 2008; 29: 1569-1577.
• 24 Fisman DN, Malcom ID, Ward ME. Echocardiographic detection of pulmonary embolism in transit: implications for institution of thrombolytic therapy. Can J Cardiol 1997; 13: 685-687.
• 25 van der Meer RW, Pattynama PMT, van Strijen MJL. et al. Right ventricular dysfunction and pulmonary obstruction index at helical CT: prediction of clinical outcome during 3-month followup in patients with acute pulmonary embolism. Radiology 2005; 235: 798-803.
• 26 Schoepf UJ, Kucher N, Kipfmueller F. et al. Right ventricular enlargement on chest computed tomography a predictor of early death in acute pulmonary embolism. Circulation 2004; 110: 3276-3280.
• 27 Qanadli SD, El Hajjam M, Vieillard-Baron A. et al. New CT index to quantify arterial obstruction in pulmonary embolism: comparison with angiographic index and echocardiography. AJR Am J Roentgenol 2001; 176: 1415-1420.
• 28 Schoepf UJ, Kucher N, Kipfmueller F. et al. Right ventricular enlargement on chest computed tomography a predictor of early death in acute pulmonary embolism. Circulation 2004; 110: 3276-3280.
• 29 Pruszczyk P, Kostrubiec M, Bochowicz A. et al. N-terminal pro-brain natriuretic peptide in patients with acute pulmonary embolism. Eur Respir J 2003; 22: 649-653.
• 30 Klok FA, Mos IC, Huisman MV. BNP levels in the prediction of adverse outcome in patients with pulmonary embolism: a meta-analysis. Am J Respir Crit Care Med. 2008 epub ahead of print.
• 31 Kucher N, Printzen G, Doernhoefer T. et al. Low pro-brain natriuretic peptide levels predict benign clinical outcome in acute pulmonary embolism. Circulation 2003; 107: 1576-1578.
• 32 Sohne M, Ten Wolde M, Boomsma F. et al. Brain natriuretic peptide in hemodynamically stable acute pulmonary embolism. J Thromb Haemost 2006; 04: 552-556.
• 33 Lippi G, Favaloro EJ. Cardiac biomarkers in pulmonary embolism. Thromb Haemost 2008; 99: 1134-1136.
• 34 Korff S, Katus H, Giannitsis E. Differential diagnosis of elevated troponins. Heart 2006; 92: 987-993.
• 35 Muller-Bardorff M, Weidtmann B, Giannitsis E. et al. Release kinetics of cardiac troponin T in survivors of confirmed severe pulmonary embolism. Clin Chem 2002; 48: 673-675.
• 36 Katus HA, Remppis A, Neumann FJ. et al. Diagnostic efficiency of troponin T measurements in acute myocardial infarction. Circulation 1991; 83: 902-912.
• 37 Yalamanchili K, Sukhija R, Aronow WS. et al. Prevalence of increased cardiac troponin I levels in patients with and without acute pulmonary embolism and relation of increased cardiac troponin I levels with inhospital mortality in patients with acute pulmonary embolism. Am J Cardiol 2004; 93: 263-264.
• 38 Punukollu G, Khan I, Gowda RM. et al. Cardiac troponin I release in acute pulmonary embolism in relation to the duration of symptoms. Int J Cardiol 2005; 99: 207-211.
• 39 Becattini C, Vedovati MC, Agnelli G. Prognostic value of troponins in acute pulmonary embolism. A meta-analysis. Circulation 2007; 116: 427-433.
• 40 Jimenez D, Diaz G, Molina J. et al. Troponin I and risk stratification of patients with acute non massive pulmonary embolism. Eur Respir J 2008; 31: 847-853.
• 41 Gallotta G, Palmieri V, Piedimonte V. et al. Increased troponin I predicts in-hospital occurrence of hemodynamic instability in patients with sub-massive or non-massive pulmonary embolism independent to clinical, echocardiographic and laboratory information. Int J Cardiol 2008; 124: 351-357.
• 42 Becattini C, Vedovati MC, Agnelli G. Diagnosis and prognosis of pulmonary embolism: focus on serum troponin. Exp Rev Mol Diag 2008; 08: 339-349.
• 43 Binder L, Pieske B, Olschewski M. et al. N-terminal pro-brain natriuretic peptide or troponin testing followed by echocardiography for risk stratification of acute pulmonary embolism. Circulation 2005; 112: 1573-1579.
• 44 Scridon T, Scridon C, Skali H. et al. Prognostic significance of troponin elevation and right ventricular enlargement in acute pulmonary embolism. Am J Cardiol 2005; 96: 303-305.
• 45 Ishii J, Ozaki Y, Lu J. et al. Prognostic value of serum concentration of heart-type fatty acid binding protein relative to cardiac troponin T on admission in the early hours of acute coronary syndrome. Clin Chem 2005; 51: 1397-1404.
• 46 Kaczynska A, Pelsers M, Bochowicz A. et al. Plasma heart-type fatty acid binding protein is superior to troponin and myoglobin for rapid risk stratification in acute pulmonary embolism. Clinica Chimica Acta 2006; 371: 117-123.
• 47 Puls M, Dellas C, Lankeit M. Et al. Heart-typer fatty acid-binding protein permits early risk stratification of pulmonary embolism Eur Heart J 2007; 28: 224-229.
• 48 Pruszczyk P, Bochowicz A, Kostrubiec M. et al. Myoglobin stratifies short term risk in acute major pulmonary embolism. Clinica Chimica Acta 2003; 338: 53-56.
• 49 Arnason T, Wells P, Forster AJ. Appropriateness of diagnostic strategies for evaluating suspected venous thromboembolism. Thromb Haemost 2007; 97: 195-201.
• 50 Aujesky D, Roy PM, Guy M. et al. Prognostic value of D-dimer in patients with pulmonary embolism. Thromb Haemost 2006; 96: 478-482.
• 51 Lankeit M, Kempf T, Dellas C. et al. Growth differentiation factor-15 for prognostic assessment of patients with acute pulmonary embolism. Am J Respir Crit Care Med 2008; 177: 1018-1025.
• 52 Kearon C, Kahn SR, Agnelli G. et al. Antithrombotic therapy for venous thromboembolic disease: American College of Chest Physician Evidence-based Clinical Practice Guidelines (8^th Edition). Chest 2008; 133: 454S-545S.